Clinical Trial Update: Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

View source ↗

Summary

This clinical trial update reports the evaluation of apatinib combined with docetaxel as a second-line treatment for advanced EGFR wild-type, non-squamous non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Jiangsu ShengDiYa Medicine Co., Ltd. | Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung | Status: UNKNOWN